Vienna, Austria, August 31 – September 4, 2008
The EFMC-ISMC 2008 Symposium is organized by the Austrian Chemical Society on behalf of the European Federation for Medicinal Chemistry (EFMC).

This symposium is recognized worldwide as one of the leading Medicinal Chemistry meetings, as proven by its large international attendance, which varies between 1200 and 1500 participants from all over Europe, but also from the United States and Asia.

The Symposium will focus on important new scientific and technological developments in the drug discovery process; particularly those relevant to medicinal chemistry. The meeting will create an environment for in-depth, informed discussions highlighting the importance of medicinal chemistry in the pharmaceutical industry, academia and drug research. It will also provide opportunities to re-emphasise the crucial position of medicinal chemistry in the drug discovery process and its pivotal role in linking and exploiting the associated biological sciences. Therefore, ISMC-2008 intends to create a forum for all scientists interested in medicinal chemistry and related fields.

Programme

Plenary Lectures

Dr. Magid ABOU-GHARBIA
(WYETH RESEARCH, Princeton, United States)

Prof. Chris DOBSON
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

Prof. Paul HERRLING
(NOVARTIS INTERNATIONAL, Basel, Switzerland)

Prof. Barbara IMPERIALI
(MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, United States)

Prof. Steven V. LEY
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

GlaxoSmithKline Award forOutstanding Achievement in the Field of Chemical Biology
EFFMC Award Lectures

The Nauta Award for Pharmacochemistry

The UCB-Ehrlich Award for Excellence in Medicinal Chemistry

The Prous Institute-Overton and Meyer Award for Technologies in Drug Discovery
1. Novel Lead Finding Approaches 2. Chemistry Strategies to Reduce Attrition in Drug Discovery 3. Emerging Drugs

Session Chair
Dr. Hans-Ulrich STILZ
(SANOFI-AVENTIS, Frankfurt/Main, Germany)
Title to be determined
Dr. Jeff BLANEY
(STRUCTURAL GENOMIX, San Diego, United States)
Title to be determined
Prof. Roderick E. HUBBARD
(UNIVERSITY OF YORK, York, United Kingdom)
Oral communication
to be selected from submitted abstracts

Session Chair
Dr. Geoffrey STEMP
(GLAXOSMITHKLINE, Harlow, United Kingdom)
From Fragment to Clinic
Dr. David REES
(ASTEX THERAPEUTICS, Cambridge, United Kingdom)
Chemical Strategies for Successful Clinical Development
Dr. Christopher N. JOHNSON
(GLAXOSMITHKLINE, Harlow, United Kingdom)
Oral communication
to be selected from submitted abstracts

Session Chair
Dr. Bernd RIEDL
(BAYER HEALTHCARE, Wuppertal, Germany)
The Discovery and Development of Rivaroxaban
Dr. Susanne ROEHRIG
(BAYER HEALTHCARE, Wuppertal, Germany)
The Discovery and Development of a Selective PI3K-Alpha Inhibitor
Dr. Carlos GARCIA-ECHEVERRIA
(NOVARTIS PHARMA, Basel, Switzerland)
Discovery of TMC278: a Next Generation NNRTI Drug, Highly Active against Human Immunodeficiency Virus Type-1
Dr. Jérôme GUILLEMONT
(JOHNSON & JOHNSON PRD, Val de Reuil, France)

4. Kinase Selectivity-Is it Necessary? (ACS) 5. Predictive ADME/Tox Methods: What to Apply When? 6. Macromolecular and Polymeric Drugs

Session Chair
Prof. David ROTELLA
(WYETH RESEARCH, Princeton, United States)
Title to be determined
Dr. Dennis POWELL
(WYETH RESEARCH, Pearl River, United States)
Title to be determined
Dr. Louis LOMBARDO
(BRISTOL-MYERS SQUIBB, , United States)
Title to be determined
Dr. Andrew THOMAS
(ASTRAZENECA R&D, Macclesfield, United Kingdom)

Session Chair
Dr. Scott BOYER
(ASTRAZENECA, Mölndal, Sweden)
Predictive ADME: Examples from the Real World
Dr. Andrew Mark DAVIS
(ASTRAZENECA R&D, Loughborough, United Kingdom)
Virtual Methods for Predicting Off-Target Pharmacology
Dr. Jordi MESTRES
(IMIM AND UNIVERSITAT POMPEU FABRA, Barcelona, Spain)
Oral communication
to be selected from submitted abstracts

Session Chair
Prof. Abraham J. DOMB
(HEBREW UNIVERSITY OF JERUSALEM, Jerusalem, Israel)
Keynote
to be selected
Title to be determined
Dr. Ronit SATCHI-FAIRANO
(TEL AVIV UNIVERSITY, Tel Aviv, Israel)
Oral communication
to be selected from submitted abstracts

7. Fragment-Based Drug Discovery (ACS)  8. Imaging Ligands and Biomarkers (EUFEPS) 9. Natural Products as Starting Points in Drug Discovery

Session Chair
Dr. Jeffrey ALBERT
(ASTRAZENECA, Wilmington, United States)
Building the Perfect Beast: Designing a Fragment-Based Drug Discovery Paradigm
Dr. Edward ZARTLER
(MERCK RESEARCH LABORATORIES, Rahway, United States)
Fragment-Based Discovery: What Has it Achieved so far?
Dr. Alexander ALEX
(PFIZER, Sandwich, United Kingdom)
Fragment-Based Methods and the Discovery of BACE-1 Inhibitors for Alzheimer’s
Dr. Jeffrey ALBERT
(ASTRAZENECA, Wilmington, United States)

Session Chair
Prof. Pia VUORELA
(ÅBO AKADEMI UNIVERSITY, Turku, Finland)
Fluorometry and FRET in Measuring Biomarkers and Monitoring Cell Signaling Cascade
Dr. Ilkka HEMMILA
(PERKINELMER LIFE SCIENCES, Turku, Finland)
Mass Sensitive Ligands Useful for Biomarker Discovery and Validation
Dr. Peter SCHULZ-KNAPPE
(PROTEOME SCIENCES, Cobham, United Kingdom)
Oral communication
to be selected from submitted abstracts

Session Chair
Dr. Erden BANOGLU
(GAZI UNIVERSITY, Ankara, Turkey)
Natural Products as Tools to Identify Novel Drug Targets and Novel Therapeutic Interventions
Dr. Gunda I. GEORG
(UNIVERSITY OF MINNESOTA, Minneapolis, United States)
How to Use The Structural Diversity of Natural Products for Drug Discovery
Dr. Philipp KRASTEL
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
Oral communication
to be selected from submitted abstracts

10. Novel Approaches for Treatment of Neurodegenerative Diseases 11. Type 2 Diabetes: The Incretin System 12. Progress in COPD and Asthma Therapy

Session Chair
Dr. Magid ABOU-GHARBIA
(WYETH RESEARCH, Princeton, United States)
Title to be determined
Prof. Hilal A. LASHUEL
(EPFL – ECUBLENS, Lausanne, Switzerland)
Title to be determined
Dr. Steve JACOBSEN
(WYETH RESEARCH, Princeton, United States)
Oral communication
to be selected from submitted abstracts

Session Chair
Prof. Koen AUGUSTYNS
(UNIVERSITY OF ANTWERP, Antwerp, Belgium)
Discovery of Sitagliptin and Rational Design of Other Novel DPP-4 Inhibitors
Dr. Tesfaye BIFTU
(MERCK & CO., Rahway, United States)
Peptidic and Nonpeptidic Glucagon-Like Peptide 1 Receptor Agonists
Dr. Jesper LAU
(NOVO NORDISK, Maaloev, Denmark)
Oral communication
to be selected from submitted abstracts

Session Chair
Dr. Matthias GRAUERT
(BOEHRINGER INGELHEIM, Biberach, Germany)
Recent Developments in CCR3 Antagonists
Dr. George V. DE LUCCA
(BRISTOL-MYERS SQUIBB, Princeton, United States)
Discovery of Potent and Highly Isoform Selective PI3Kg Inhibitors
Dr. Thomas RÜCKLE
(MERCK SERONO, Geneva, Switzerland)
Oral communication
to be selected from submitted abstracts

13. Allosteric Modulation and GPCR Drug Discovery 14. Oncology 15. Immunology & Immunomodulation

Session Chair
Prof. Rob LEURS
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)
The Potential of Allosteric Modulation for GPCR Drug Discovery
Prof. Arthur CHRISTOPOULOS
(MONASH UNIVERSITY, Clayton, Australia)
Therapeutic Opportunities for Small Molecule Modulators of Chemokine Receptors
Dr. Thomas J. SCHALL
(CHEMOCENTRYX, Mountain View, United States)
Oral communication
to be selected from submitted abstracts

Session Chair
Dr. Graham WARRELLOW
(UCB SA, Cambridge, United Kingdom)
Eg5 Inhibitors
Dr. Christopher COX
(MERCK RESEARCH LABORATORIES, West Point, United States)
Allosteric Akt Inhibitors
Dr. George HARTMANN
(MERCK RESEARCH LABORATORIES, West-Point, United States)
PLK1 Inhibitor (BI-2536)
Dr. Matthias HOFFMANN
(BOEHRINGER INGELHEIM, Biberach, Germany)

Session Chair
Dr. Katerina LEFTHERIS
(BRISTOL-MYERS SQUIBB, Princeton, NJ, United States)
Current Aspects and Future Trends in Immunomodulation
Dr. Murray MCKINNON
(BRISTOL-MYERS SQUIBB, Princeton, United States)
Advances in Targeting Glucocorticoids
Dr. Hartmut REHWINKEL
(SCHERING, Berlin, Germany)
Oral communication
to be selected from submitted abstracts

16. Antispsychotic Targets 17. Antivirals 18. Pain

Session Chair
Prof. Klaus P. BOGESO
(H. LUNDBECK, Valby, Denmark)
NK3 Receptors
Prof. Klaus SIMONSEN
(H. LUNDBECK, Valby, Denmark)
PDE10 Inhibitors
Dr. Patrick Robert VERHOEST
(PFIZER GLOBAL RESEARCH, Groton, United States)
Oral communication
to be selected from submitted abstracts

Session Chair
Dr. Maria Jose CAMARASA
(SEQT, Madrid, Spain)
Title to be determined
Dr. Jan BALZARINI
(REGA INSTITUTE FOR MEDICAL RESEARCH, Leuven, Belgium)
Lethal Mutagenesis as a New Antiviral Strategy
Prof. Esteban DOMINGO
(UNIVERSIDAD AUTONOMA DE MADRID, Madrid, Spain)
Oral communication
to be selected from submitted abstracts

Session Chair
Dr. Mark DUGGAN
(AMGEN, Cambridge, United States)
Title to be determined
Dr. Stefan MCDONOUGH
(AMGEN, Cambridge, United States)
Nav1.7 Inhibitors – Discovery and Development
Dr. Joseph L. DUFFY
(MERCK RESEARCH LABORATORIES, Rahway, United States)
Oral communication
Dr. Graham N. MAW
(PFIZER, Sandwich, United Kingdom)

19. Exploring the Chemical Space 20. Chemokines 21. Systems Level Research Informs Drug Target Identification and Therapy Design

Session Chair
Profs. Herbert WALDMANN & STEFAN WETZEL
(MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)
Title to be determined
Prof. Gisbert SCHNEIDER
(JOHANN WOLFGANG GOETHE UNIVERSITY, Frankfurt, Germany)
Title to be determined
Dr. Antonio MACCHIARULO
(UNIVERSITY OF PERUGIA, Perugia, Italy)
Title to be determined
Prof. Jean-Louis REYMOND
(UNIVERSITÄT BERN, Bern, Switzerland)
Title to be determined
Dr. Stefan WETZEL
(MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)

Session Chair
Prof. Gerhard ECKER
(UNIVERSITY OF VIENNA & EFMC, Vienna, Austria)
Title to be determined
Prof. Nobutaka FUJII
(KYOTO UNIVERSITY, Kyoto, Japan)
Selective Dual CCR2/5 Antagonists
Dr. Wolfgang MILTZ
(NOVARTIS PHARMA, Basel, Switzerland)
Oral communication
to be selected from submitted abstracts

Session Chair
Prof. Harel WEINSTEIN
(CORNELL UNIVERSITY, New York, United States)
Drug Discovery, Drug Delivery and Therapeutic Monitoring by Molecular, Cellular and Functional Imaging of Atherothrombosis
Dr. Zahi A. FAYAD
(MOUNT SINAI SCHOOL OF MEDICINE, New York, United States)
Understanding Drug Mechanisms and Designing Therapy at the Systems Level of the Functional Human Interactome
Prof. Gianni CESARENI
(UNIVERSITY OF ROME ‘TOR VERGATA’, Rome, Italy)
Special Structural, Dynamic and Functional Characteristics of Membrane Proteins and their Signaling Partners that Determine the Mode and Putative Success of Therapy Design Targeting Cellular Signaling Systems.
Prof. Harel WEINSTEIN
(CORNELL UNIVERSITY, New York, United States)

22. New Computational Approaches Supporting Drug Design 23. Druggability of Protein-Protein Interactions 24. Systems Biology and Medicinal Chemistry

Session Chair
Dr. Jordi MESTRES
(IMIM AND UNIVERSITAT POMPEU FABRA, Barcelona, Spain)
Overview on New Computational Tools Supporting Drug Design
Prof. Tudor I. OPREA
(UNIVERSITY OF NEW MEXICO, Albuquerque, United States)
Novel Tools for Data Gathering
Dr. Muthukumarasamy KARTHIKEYAN
(NATIONAL CHEMICAL LABORATORY, Pune, India)
Novel Tools for Data Classification
Dr. Ansgar SCHUFFENHAUER
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
Novel Tools for Data Exploitation
Dr. Elisabet GREGORI-PUIGJANE
(CHEMOTARGETS, Barcelona, Spain)

Session Chair
Dr. Peter NUSSBAUMER
(NOVARTIS, Vienna, Austria)
Title to be determined
Dr. Leonard J. PAGLIARO
(BIOIMAGE, Soeborg, Denmark)
Oral communication
to be selected from submitted abstracts
Oral communication
to be selected from submitted abstracts
Oral communication
to be selected from submitted abstracts

Session Chair
Prof. Christian NOE
(UNIVERSITY OF VIENNA, Vienna, Austria)
Network Based Drug Discovery
Prof. Hans WESTERHOFF
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)
Title to be determined
Prof. Christian NOE
(UNIVERSITY OF VIENNA, Vienna, Austria)
Oral communication
to be selected from submitted abstracts

25. Structure Based Drug Design (AFMC) 26. Modulators of Adenosine and P2Y Receptors 27. Addressing Therapeutic Complexity in Oncology with Med. Chem.

Session Chair
Prof. Esin AKI-SENER
(ANKARA UNIVERSITY, Ankara, Turkey)
Quantum Chemical Calculation of Protein-Ligand Interaction
Prof. Isao NAKANISHI
(KYOTO UNIVERSITY, Kyoto, Japan)
Title to be determined
Dr. Jose VARGHESE
(CSIRO, Parkville, Australia)
Oral communication
to be selected from submitted abstracts

Session Chair
Prof. Kenneth A. JACOBSON
(NIDDK, Bethesda, United States)
Engineering of Purine Receptors and Their Ligands
Prof. Kenneth A. JACOBSON
(NIDDK, Bethesda, United States)
Title to be determined
Prof. Pier Giovanni BARALDI
(UNIVERSITY OF FERRARA, Ferrara, Italy)
Allosteric Modulation of Purine Receptors
Prof. Ad P. IJZERMAN
(LEIDEN/AMSTERDAM CENTER FOR DRUG RESEARCH, Leiden, The Netherlands)

Session Chair
Dr. Graeme ROBERTSON
(SIENA BIOTECH, Siena, Italy)
Alternatives to Kinase Inhibitors for Cancer Therapies
Prof. Giovanni GAVIRAGHI
(SIENA BIOTECH, Siena, Italy)
Endothelin Converting Enzyme Inhibitors as Anticancer Agents for Human Glioblastoma. A Comparison with Endothelin Receptor Antagonists
Dr. Lucienne JUILLERAT
(CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS, Lausanne, Switzerland)
Novel Kinase Inhibitors
Dr. Dirk HEERDING
(GLAXOSMITHKLINE, Collegeville, United States)

Read More →
Share:

The agenda is now available for Select Conferences inaugural Ion Channel Targets conference and exhibition being held in Waltham, Boston, 20-21 September 2005. With easy worldwide access and inexpensive registration fees a high degree of interest is anticipated. Early registration is therefore recommended as delegate numbers will be limited.

We are delighted to announce a top quality agenda featuring 4 sessions and 20 speakers assembled from academia and industry. Chairing the first session, Ion Channels in Drug Discovery, is Dr. Michael Xie who is currently Associated Director of Biology at Synta Pharmaceuticals. On the afternoon of the first day Dr. Chris Mathes, Vice-President and General Manager of Sophion, will chair Advances in Ion Channel Technology and Screening. The second day will open with Ion Channels in Disease Biology chaired by our key note speaker Prof. David Clapham. He is currently Professor of Cardiovascular Research Investigator at the Howard Hughes Medical Institute and Professor of Neurobiology, Harvard Medical School. The meeting will close with Target Identification and Validation chaired by Dr. Maria Garcia, who is a Distinguished Senior Investigator in the Department of Ion Channels at Merck Research Laboratories.

In order to ensure the widest possible audience for our speakers registration fees start at just $399. So, if you want to see the latest research and equipment in ion channels whilst networking with your peers then this event is both affordable and unmissable.

Agenda

Day One 20th September

09:00 Ion Channels in Drug Discovery
Chaired by Dr. Michael Xie – Synta Pharmaceuticals

09:05 Combination Screening of Ion Channel Targets to Reduce False Positive Rate
Dr. Christopher Fanger, Hydra Biosciences

09:40 Ion Channel Targets in Drug Design for Cancer Therapeutics
Dr. Amit Banerjee, Wayne State University

10:15 Coffee and Networking in Exhibition

10:45 Novel Antagonists of Human Kv4.3: HT Ion Channel Screening in Transgenic C. elegans.
Dr. Andreas Kopke, Devgen nv

11:20 HERG, Repolarization and Sudden Cardiac Death
Dr. Arthur M. Brown, ChanTest, Inc.

11:55 Ion Channel Drug Discovery in Non-excitable Cells
Dr. Michael Xie, Synta Pharmaceuticals

12:30 Lunch and Networking in Exhibition

13:45 Advances in Ion Channel Technology and Screening
Chaired by Dr. Chris Mathes – Sophion Biosciences

13:50 Automated Patch Clamp Technology: Evaluation of QPatch® for Voltage Gated Na-channel Characterization
Dr. Mads Peder Gersdorff Korsgaard – Neurosearch

14:25 Utilising Ion Channel Cell Lines and High Throughput Electrophysiology in the Context of Drug Discovery and Development
Dr. Ray Helliwell, Cytomyx

15:00 Application of the Aequorin Assay Technology for Ion Channel Drug Discovery
Dr. Sandra Arpino, GlaxoSmithKline

15:35 Coffee and Networking in Exhibition

16:05 Cell Volume Cytometry

Read More →
Share: